CB
CALIWAY BIOPHARMACEUTICALS
4Press Releases
Latest Press Releases (4)
CALIWAY BIOPHARMACEUTICALS
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum’s Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
NEW TAIPEI CITY, Sept. 22, 2026
CALIWAY BIOPHARMACEUTICALS
Caliway’s CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
NEW TAIPEI CITY, Aug. 25, 2026
